9 July 2020 - - US-based clinical research organisation and precision cancer therapy company Certis Oncology Solutions is offering mobile COVID-19 testing services to area businesses, the company said.

Certis Oncology Solutions is one of few area laboratories licensed by the California Department of Public Health and Centers for Medicare and Medicaid Services, and is CLIA-certified for high complexity testing, a requirement for compliance with California and US clinical laboratory laws.

That certification, in combination with Certis' in-house molecular biologists and advanced analytical instrumentation, enabled Certis to quickly pivot in response to the COVID-19 pandemic.

The company will offer an FDA-approved viral test, which employs nasopharyngeal swabbing and Reverse Transcription Polymerase Chain Reaction (RT-PCR) analyses, widely considered to be the gold standard in biological identification.

Certis will bring testing to individual work sites--minimizing exposure risk and reducing employees' time away from work.

Nasopharyngeal swabbing is performed by Licensed Practice Nurses, and samples are analyzed in Certis' Sorrento Valley-based laboratory.

The company aims to deliver results in 24-48 hours.

Certis Oncology Solutions was formed in 2016 with the mission to provide individualised treatment options to cancer patients.

Its technology enables oncologists to determine with precision the most effective available therapies to treat each patient's unique disease.